Studies On The Role And Correlation Of RKIP And P-ERK In Epithelial Ovarian Cancer

Objectives:To investigate the expression and correlation of Raf kinase inhibitor protein(RKIP) and phosphorylation extracellular signal-regulated kinase (P-ERK) and the role and mechanism of the invision and metastasis in epithelial ovarian carcinoma.Methods:The expression of RKIP and P-ERK were detected in76cases of epithelial ovarian cancer tissues,35of epithelial ovarian benign neoplasms tissues,22of normal ovarian tissues by immunohistochemical technology(S-P). Statistical analysis was used to compared the expression of RKIP and P-ERK with clinical and pathological parameters in epithelial ovarian cancer and the correlation was analyzed.Results:l.The expression rate of RKIP in epithelial ovarian cancer, epithelial ovarian benign neoplasm and normal ovarian tissues was23.60%,69.10%,95.50%,RKIP expression was significant lower in epithelial ovarian cancer than that benign neoplasms and normal ovarian, the difference was significant (P<0.01).2. The expression rate of P-ERK in epithelial ovarian cancer, epithelial ovarian benign neoplasms and normal ovarian tissues was86.60%,40.00%,18.20%, P-ERK expression was significant higher in epithelial ovarian cancer than that benign neoplasms and normal ovarian, the difference was significant (P<0.0l).3. The expression rate of RKIP in epithelial ovarian cancer was23.6%, the expression rate of P-ERK in epithelial ovarian cancer was86.60%, the expression of RKIP was negatively correlated with P-ERK(r=-0.462) in the epithelial ovarian cancer.4.The expressions rate of RKIP in well and moderately differentiated tissues was10%,the expression rate in poorly differentiated tissues was26.79%, P=0.000, the difference was significant(P<0.01);The expressions rate of RKIP in I/II stages was55.56%, the expressions rate in III/IV stages was4.08%, P=0.000, the difference was significant(P<0.0l); The expressions rate of RKIP in the tissues with lymph node transferred was5.56%,the expression without lymph node transferred was 37.50%,p=0.001, the difference was significant(P<0.01); The expression rate of RKIP in peoples who was≤50-year-old was33.33%,the expression in>50-yesr-old was16.32%,P=0.089, the difference was not significant(P>0.05);The expression rate of RKIP in serosity was25.45％.the expression in others was14.29%.P=0.296, the difference was not significant(P>0.05).5. The expressions rate of P-ERK in well and moderately differentiated tissues was50%,the expression rate in poorly differentiated tissues was96.43%, P=0.000, the difference was significant P<0.01);The expressions rate of P-ERK in Ⅰ/Ⅱ stages was62.96%, the expressions rate in III/IV stages was95.92%, P=0.000, the difference was significant (P＜0.01); The expressions rate of P-ERK in the tissues with lymph node transferred was97.22%,the expression without lymph node transferred was72.50%,p=0.003, the difference was significant (P＜0.01); The expression rate of P-ERK in peoples who was≤50-year-old was74.07%,the expression in>50-yesr-old was89.80%,P=0.072, the difference was not significant(P>0.05);The expression rate of P-ERK in serosity was85.45%,the expression in others was80.95%,P=0.961, the difference was not significant(P>0.05).Conclusions:1. Reduced expression of RKIP in epithelial ovarian cancer, while P-ERK was abnormal activation, They maybe participate the occurrence of epithelial ovarian cancer.2. The expression of RKIP is lower with tumor differentiation,clinical staging and lymphnode metastasis,The results indicate that RKIP play an important role in inhibitor invision and migration of epithelial ovarian cancer.3. The expression of P-ERK is higher with tumor differentiation,clinical staging and lymphnode metastasis,The results indicate that RKIP play an important role in promoting metastasis and invision of epithelial ovarian cancer.4.There was negative correlation between the expressions of RKIP and P-ERK in epithelial ovarian cancer; Probably, The mechanism maybe activate the ERK signaling pathway and promoting invision and metastasis of epithelial ovarian cancer.